{
    "clinical_study": {
        "@rank": "43427", 
        "arm_group": [
            {
                "arm_group_label": "Ivabradine", 
                "arm_group_type": "Active Comparator", 
                "description": "Ivabradine 10 mg once"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether Ivabradine is an effective treatment for\n      postural tachycardia syndrome."
        }, 
        "brief_title": "The Effect of Ivabradine on Patients With Postural Tachycardia Syndrome", 
        "condition": "Postural Tachycardia Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Tachycardia", 
                "Postural Orthostatic Tachycardia Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients diagnosed with POTS by the following criteria:\n\n               1. The presence of characteristic orthostatic symptoms of the POTS  for at least\n                  six months.\n\n               2. An increase in the heart rate of at least 30 beats per minute (without\n                  concomitant significant decrease in blood pressure of more than 20/10 mmHg)\n                  within 10 minutes after assuming a standing position (or during tilt test) on at\n                  least 3 separate occasions.\n\n               3. No other concomitant diseases that could explain the symptoms of POTS.\n\n                  Exclusion Criteria:\n\n               1. History of systemic illness capable of affecting of affecting autonomic function\n                  (eg, diabetes mellitus, SLE).\n\n               2. History of cardiovascular disease.\n\n               3. History of smoking, drug or alcohol abuse.\n\n               4. Pregnancy, and also uncontrolled thyroid or adrenal disorders.\n\n               5. Using any drug metabolized by cytochrome P450 3A4 enzyme during the last 72\n                  hours."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01761825", 
            "org_study_id": "TASMC-12-JG-547-CTIL"
        }, 
        "intervention": {
            "arm_group_label": "Ivabradine", 
            "intervention_name": "ivabradine", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 3, 2013", 
        "number_of_arms": "2", 
        "official_title": "The Effect of \"Funny\" Channel Blocker Ivabradine on Patients With Postural Tachycardia Syndrome.", 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "the change in heart rate after the administration of Ivabradine", 
                "safety_issue": "Yes", 
                "time_frame": "60 minutes , during the whole trial"
            }, 
            {
                "measure": "the change in blood pressure after the administration of Ivabradine", 
                "safety_issue": "Yes", 
                "time_frame": "60 minutes"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01761825"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Tel-Aviv Sourasky Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tel-Aviv Sourasky Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}